Eli Lilly Invests Big in Psychedelic Medicine

Eli Lilly, a major drug company, is making a big move into psychedelic medicine. The company plans to buy AtaiBeckley for $2.8 billion. This deal shows a growing interest in new ways to treat mental health problems.

AtaiBeckley develops drugs using compounds like DMT and MDMA. These substances come from plants and fungi. Scientists are exploring their power to help with conditions like depression and anxiety. These drugs are still experimental, but early results look promising.

This purchase gives Eli Lilly access to these new treatments. It also signals a shift in how the medical world views psychedelic compounds. Doctors once saw these substances as dangerous. Now, they see them as possible keys to better health.

The investment could lead to more research. It might speed up the approval of new medicines. For patients, this could mean more options for hard-to-treat mental health issues in the future.

Source: CNBC